DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hypopituitarism — screening already-approved drugs against its 37-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHypopituitarism maps to a 37-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hypopituitarism is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fragile histidine triad diadenosine triphosphatase (FHIT) — FHIT is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet frudrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1FIT · 1.85 Å · ligand beta-D-fructofuranose (FRU). Experimental structure, not a prediction.
What the evidence adds up to
Hypopituitarism is defined as deficient secretion of one or more of the eight pituitary hormones, caused by disease of the pituitary gland or of the hypothalamus. If most or all hormones are deficient the term panhypopituitarism is used. Clinical manifestations depend on the extent of the deficiency and can be non-specific — fatigue, hypotension, cold intolerance — or more indicative, such as growth retardation, impotence, or infertility. The condition is associated with increased morbidity and mortality and requires lifelong follow-up.
A 1993 study of ten children with ectopic posterior pituitary tissue on MRI found that those with a non-visualised pituitary stalk had panhypopituitarism, while those with an attenuated stalk retained partial anterior pituitary function. A 1999 case report describes acute adrenal insufficiency presenting as hypoglycaemic seizures and coma 24 hours after caesarean delivery, which was found to be isolated adrenocorticotrophic hormone deficiency. The authors note that adrenal crisis in pregnancy is rare but life-threatening, and that appropriate treatment must not be delayed.
A 2024 bidirectional Mendelian randomisation study using genome-wide association data examined 731 immune cell phenotypes and found evidence for bidirectional causal links between hypopituitarism and B cells, T cells, Tregs, dendritic cells, monocytes, and myeloid cells. One B-cell phenotype was associated with increased hypopituitarism risk, two B-cell phenotypes appeared protective, seven T-cell phenotypes appeared protective, and seven Treg phenotypes were associated with increased risk. Reverse analysis found hypopituitarism positively associated with 30 additional immune cell phenotypes and negatively associated with 17. The authors conclude the findings underscore an immune-mediated pathway in hypopituitarism pathogenesis.
What is still missing are prospective studies that confirm these genetic associations in patients, trials that test whether modulating specific immune cell types alters hormone deficiency, and any stratification of patients by immune phenotype or MRI stalk appearance to guide treatment. No drug is mentioned in any of these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American journal of diseases of children · 1993 · 28 citations
Pituitary Stalk and Ectopic Hyperintense T1 Signal on Magnetic Resonance Imaging
AbstractOBJECTIVE: To determine if improved delineation of hypothalamic-pituitary neuroanatomy by magnetic resonance imaging, especially the posterior pituitary hyperintense T1 signal, can be correlated with anterior and posterior pituitary endocrine function. DESIGN: Children with ectopic posterior pituitary tissue were identified at the Endocrine Clinic of the Children's Hospital of Pittsburgh (Pa) and their records were reviewed. PARTICIPANTS: Ten children with ectopic posterior pituitary tissue. MEASUREMENTS: Anterior pituitary hormone status, determined by standard testing, was correlated with the morphologic anomalies of the hypothalamic-pituitary region on magnetic resonance imaging. RESULTS: Patients were categorized by the appearance of the pituitary stalk based on the magnetic resonance image: attenuation of the stalk (group 1) or nonvisualization of the stalk (group 2). Patients in group 1 retained partial anterior pituitary function. Patients in group 2 had panhypopituitarism. CONCLUSION: Prospective evaluation of affected individuals may provide insight into the pathophysiologic mechanisms of idiopathic hypopituitarism.
Acute Adrenal Insufficiency During Pregnancy and Puerperium: Case Report and Literature Review
AbstractUNLABELLED: Acute adrenal dysfunction during pregnancy is rare. Nevertheless, adrenal insufficiency can present as an adrenal crisis, and may be life threatening. There is a wide range of clinical symptoms and signs, and the differential diagnosis is challenging. A full adrenal and pituitary evaluation, both structural and hormonal, must be performed to reach the correct diagnosis, and appropriate treatment must not be delayed. A case is presented of acute adrenal insufficiency that occurred 24 hours after a cesarean delivery. The initial symptoms included hypoglycemic seizures and coma. The workup, both hormonal and structural, revealed isolated adrenocorticotrophic hormone deficiency. This considers this case and reviews the differential diagnosis, diagnostic workup, and the treatment of adrenal dysfunction in pregnancy and the puerperium, as well as the obstetric outcome in women suffering from this disorder. TARGET AUDIENCE: Obstetricians & Gynecologists, Family Physicians. LEARNING OBJECTIVES: After completion of this article, the reader will be able to understand the various presentations of hypopituitarism, the various etiologies of this condition, and the appropriate work up and management of a patient with hypopituitarism.
World Neurosurgery · 2024 · 6 citations · open access
Causal Relationship Between Immune Cells and Hypopituitarism: Bidirectional Mendelian Randomization Study
AbstractBACKGROUND: Hypopituitarism, one or more pituitary hormones inefficiently produced by the anterior pituitary or released from the posterior pituitary to adapt to the needs of the organism. Existing epidemiological data show that immune-mediated diffuse infiltration of the anterior pituitary is important in the development of hypopituitarism. However, the precise connection between immune cells and hypopituitarism remains unclear. This study aimed to elucidate the potential causal links between the 731 immune cell types and hypopituitarism risk. METHODS: Based on data from a genome-wide association study, a bidirectional two-sample Mendelian randomization analysis was performed using 5 methods to explore the potential influence of immune cell phenotypes on hypopituitarism. Sensitivity analyses were conducted to examine the robustness of these findings. RESULTS: Our findings support that B cells, T cells, Tregs, dendritic cells, monocytes, and myeloid cells each have a bidirectional influence on hypopituitarism. One B-cell phenotype was associated with increased hypopituitarism risk, while 2 B-cell phenotypes play a protective role in hypopituitarism. Moreover, 7 T-cell phenotypes demonstrate significant protective properties on hypopituitarism. Seven Tregs were associated with increased hypopituitarism risk. Furthermore, one monocyte was identified to be significantly associated with hypopituitarism risk. In addition, reverse Mendelian randomization analysis revealed that hypopituitarism was positively associated with 30 additional immune cell phenotypes and negatively associated with 17 immune cells. CONCLUSIONS: Our investigation shed light on the intricate potential relationship between immune cells and hypopituitarism via genetic methods, underscoring the immune-mediated pathway in hypopituitarism pathogenesis, thereby offering valuable insights for future clinical investigations.
Endocrinology and Disorders · 2017 · 0 citations · open access
Growth Hormone Deficiency in Children and Adult Patients with Hypopituitarism: Challenges in the Diagnosis and Management
AbstractHypopituitarism is the decreased (hypo) secretion of one or more of the eight hormones normally produced by the pituitary gland at the base of the brain.If there is decreased secretion of one specific pituitary hormone, the condition is known as selective hypopituitarism. If there is decreased secretion of most or all pituitary hormones, the term panhypopituitarism is used. Hypopituitarism is a complex medical condition associated with increased morbidity and mortality, requires complicated treatment regimens, and necessitates lifelong follow up by the endocrinologist.
Zenodo (CERN European Organization for Nuclear Research) · 2020 · 0 citations · open access
HYPOPITUITARISM
AbstractHypopituitarism is defined as deficiency of one or more hormones of the pituitary gland which can result from diseases of the pituitary gland or from diseases of the hypothalamus causing diminished secretion of hypothalamic releasing hormones, thereby reducing secretion of the corresponding pituitary hormones.Clinical manifestations depend on the extent of hormone deficiency and may be non-specific, such as fatigue, hypotension, cold intolerance, or more indicative such as growth retardation or impotence and infertility in GH and gonadotropin deficiency.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
